Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela RizzoAgostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti, Giuliana Alimena

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Dasatinib (DAS) has been l icensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.

Original languageEnglish
Pages (from-to)536-540
Number of pages5
JournalNeoplasia (United States)
Volume18
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Comorbidity
Dasatinib
Leukemia, Myeloid, Chronic Phase
Pleural Effusion
Cytogenetics
Clinical Trials
Safety

ASJC Scopus subject areas

  • Cancer Research

Cite this

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. / Latagliata, Roberto; Stagno, Fabio; Annunziata, Mario; Abruzzese, Elisabetta; Iurlo, Alessandra; Guarini, Attilio; Fava, Carmen; Gozzini, Antonella; Bonifacio, Massimiliano; Sorà, Federica; Leonetti Crescenzi, Sabrina; Bocchia, Monica; Crugnola, Monica; Castagnetti, Fausto; Capodanno, Isabella; Galimberti, Sara; Feo, Costanzo; Porrini, Raffaele; Pregno, Patrizia; Rizzo, Manuela; Antolino, Agostino; Mauro, Endri; Sgherza, Nicola; Luciano, Luigiana; Tiribelli, Mario; Russo Rossi, Antonella; Trawinska, Malgorzata; Vigneri, Paolo; Breccia, Massimo; Rosti, Gianantonio; Alimena, Giuliana.

In: Neoplasia (United States), Vol. 18, No. 9, 01.09.2016, p. 536-540.

Research output: Contribution to journalArticle

Latagliata, R, Stagno, F, Annunziata, M, Abruzzese, E, Iurlo, A, Guarini, A, Fava, C, Gozzini, A, Bonifacio, M, Sorà, F, Leonetti Crescenzi, S, Bocchia, M, Crugnola, M, Castagnetti, F, Capodanno, I, Galimberti, S, Feo, C, Porrini, R, Pregno, P, Rizzo, M, Antolino, A, Mauro, E, Sgherza, N, Luciano, L, Tiribelli, M, Russo Rossi, A, Trawinska, M, Vigneri, P, Breccia, M, Rosti, G & Alimena, G 2016, 'Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia', Neoplasia (United States), vol. 18, no. 9, pp. 536-540. https://doi.org/10.1016/j.neo.2016.07.005
Latagliata, Roberto ; Stagno, Fabio ; Annunziata, Mario ; Abruzzese, Elisabetta ; Iurlo, Alessandra ; Guarini, Attilio ; Fava, Carmen ; Gozzini, Antonella ; Bonifacio, Massimiliano ; Sorà, Federica ; Leonetti Crescenzi, Sabrina ; Bocchia, Monica ; Crugnola, Monica ; Castagnetti, Fausto ; Capodanno, Isabella ; Galimberti, Sara ; Feo, Costanzo ; Porrini, Raffaele ; Pregno, Patrizia ; Rizzo, Manuela ; Antolino, Agostino ; Mauro, Endri ; Sgherza, Nicola ; Luciano, Luigiana ; Tiribelli, Mario ; Russo Rossi, Antonella ; Trawinska, Malgorzata ; Vigneri, Paolo ; Breccia, Massimo ; Rosti, Gianantonio ; Alimena, Giuliana. / Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. In: Neoplasia (United States). 2016 ; Vol. 18, No. 9. pp. 536-540.
@article{8a77d047ac284180994ef99c21f004ae,
title = "Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia",
abstract = "Dasatinib (DAS) has been l icensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7{\%}) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6{\%}) were low risk, 39 (60.0{\%}) intermediate risk, and 20 (30.8{\%}) high risk, whereas 3 (4.6{\%}) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0{\%}), whereas 11 patients (17.0{\%}) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3{\%}) and 12 (18.5{\%}) patients, respectively. Overall, 10 patients (15.4{\%}) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5{\%}) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3{\%}) a complete cytogenetic response and in 50/65 (76.9{\%}) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.",
author = "Roberto Latagliata and Fabio Stagno and Mario Annunziata and Elisabetta Abruzzese and Alessandra Iurlo and Attilio Guarini and Carmen Fava and Antonella Gozzini and Massimiliano Bonifacio and Federica Sor{\`a} and {Leonetti Crescenzi}, Sabrina and Monica Bocchia and Monica Crugnola and Fausto Castagnetti and Isabella Capodanno and Sara Galimberti and Costanzo Feo and Raffaele Porrini and Patrizia Pregno and Manuela Rizzo and Agostino Antolino and Endri Mauro and Nicola Sgherza and Luigiana Luciano and Mario Tiribelli and {Russo Rossi}, Antonella and Malgorzata Trawinska and Paolo Vigneri and Massimo Breccia and Gianantonio Rosti and Giuliana Alimena",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.neo.2016.07.005",
language = "English",
volume = "18",
pages = "536--540",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

AU - Latagliata, Roberto

AU - Stagno, Fabio

AU - Annunziata, Mario

AU - Abruzzese, Elisabetta

AU - Iurlo, Alessandra

AU - Guarini, Attilio

AU - Fava, Carmen

AU - Gozzini, Antonella

AU - Bonifacio, Massimiliano

AU - Sorà, Federica

AU - Leonetti Crescenzi, Sabrina

AU - Bocchia, Monica

AU - Crugnola, Monica

AU - Castagnetti, Fausto

AU - Capodanno, Isabella

AU - Galimberti, Sara

AU - Feo, Costanzo

AU - Porrini, Raffaele

AU - Pregno, Patrizia

AU - Rizzo, Manuela

AU - Antolino, Agostino

AU - Mauro, Endri

AU - Sgherza, Nicola

AU - Luciano, Luigiana

AU - Tiribelli, Mario

AU - Russo Rossi, Antonella

AU - Trawinska, Malgorzata

AU - Vigneri, Paolo

AU - Breccia, Massimo

AU - Rosti, Gianantonio

AU - Alimena, Giuliana

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Dasatinib (DAS) has been l icensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.

AB - Dasatinib (DAS) has been l icensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.

UR - http://www.scopus.com/inward/record.url?scp=84992402708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992402708&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2016.07.005

DO - 10.1016/j.neo.2016.07.005

M3 - Article

AN - SCOPUS:84992402708

VL - 18

SP - 536

EP - 540

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 9

ER -